Status:

RECRUITING

A Study of Oral Kavalactones Effect on Nurses

Lead Sponsor:

Mayo Clinic

Conditions:

Stress

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This research study is being done to assess the impact of taking Kava extract (Piper methysticum), a dietary supplement on cortisol in a healthy nursing population.

Eligibility Criteria

Inclusion

  • Surgical services nurses at Mayo Clinic in Rochester, MN.
  • Able to participate fully in all aspects of the study.
  • Willing to use birth control for the duration of the study (if of childbearing potential).
  • Understood and signed study informed consent.

Exclusion

  • Pregnant, nursing, or trying to conceive.
  • Persons with a menstrual cycle who are not willing and able to use an approved contraceptive during the study (female sterilization (tubal ligation, hysterectomy), IUD or another implant, oral or injectable contraceptive, contraceptive patch/ring, diaphragm/cervical cap, male sterilization (vasectomy), male condom, female condom, sponge/spermicide) (Persons who do not have sex with men can participate without the use of an approved contraceptive).
  • Use of kava or kava-containing products within the past 8 weeks.
  • Any prior adverse reaction or known sensitivity or allergy to kava or related botanicals (peppers).
  • Use of acetaminophen that cannot be discontinued or replaced with an NSAID during the study.
  • Use of oral corticosteroids (e.g., hydrocortisone) or other steroids (e.g., prednisone).
  • Alcohol use greater than 1 drink per day.
  • Use of kratom within the past 8 weeks.
  • Recent history of clinical depression or anxiety diagnosis.
  • Known significant liver disease or dysfunction.
  • Known significant kidney disease or dysfunction.
  • Known Addison's or Cushing's Disease.
  • Known catecholamine imbalance or medication use which influences catecholamine levels.
  • History or current diagnosis of cancer (except for successfully treated basal cell carcinoma diagnosed less than 5 years prior to screening or cancer in full remission more than 5 years after diagnosis).
  • Recent history or acute disease or unstable medical condition.
  • Surgery planned during the course of the trial.
  • A known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence.

Key Trial Info

Start Date :

August 5 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 31 2026

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT06177535

Start Date

August 5 2024

End Date

July 31 2026

Last Update

November 24 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Mayo Clinic Minnesota

Rochester, Minnesota, United States, 55905